文献速递肝病消化道肿瘤与早癌

基于细胞代谢的肝纤维化、肝修复与肝细胞癌治疗

Cell metabolism-based therapy for liver fibrosis, repair, and hepatocellular carcinoma.
PubMed 文献 · Hepatology · 2023-05-23

综述探讨慢性肝损伤进展至纤维化、异常再生及肝细胞癌过程中上皮细胞与微环境的代谢对话,提出靶向关键效应肝细胞内在代谢通路可能干预这一致病序列。

要点

  • 慢性肝损伤进展至纤维化、异常再生及肝细胞癌由上皮细胞与免疫、成纤维及内皮细胞间对话失调驱动。
  • 目前尚无抗纤维化治疗,肝细胞癌药物治疗限于酪氨酸激酶抑制剂和靶向肿瘤微环境的免疫治疗。
  • 上皮细胞与非实质细胞代谢重编程在疾病各阶段均关键,靶向特定代谢通路可能为治疗方向。

核心结论

  • 调控关键效应肝细胞的内在代谢可能打断从慢性肝损伤到纤维化/肝硬化、再生及肝细胞癌的致病序列。

研究设计与样本

  • 综述,检索范围及方法原文未报告。

主要发现

  • 慢性肝损伤进展至纤维化、异常肝再生及肝细胞癌由上皮细胞与微环境(尤其免疫细胞、成纤维细胞及内皮细胞)间对话失调驱动。
  • 目前尚无抗纤维化治疗,肝细胞癌药物治疗限于酪氨酸激酶抑制剂和靶向肿瘤微环境的免疫治疗。
  • 上皮细胞与非实质细胞的代谢重编程在疾病进展各阶段均关键。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Progression of chronic liver injury to fibrosis, abnormal liver regeneration, and HCC is driven by a dysregulated dialog between epithelial cells and their microenvironment, in particular immune, fibroblasts, and endothelial cells. There is currently no antifibrogenic therapy, and drug treatment of HCC is limited to tyrosine kinase inhibitors and immunotherapy targeting the tumor microenvironment. Metabolic reprogramming of epithelial and nonparenchymal cells is critical at each stage of disease progression, suggesting that targeting specific metabolic pathways could constitute an interesting therapeutic approach. In this review, we discuss how modulating intrinsic metabolism of key effector liver cells might disrupt the pathogenic sequence from chronic liver injury to fibrosis/cirrhosis, regeneration, and HCC.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Gilgenkrantz H, Paradis V, Lotersztajn S, et al. Cell metabolism-based therapy for liver fibrosis, repair, and hepatocellular carcinoma. Hepatology. 2023. PMID: 37212145. doi:10.1097/HEP.0000000000000479

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。